370 related articles for article (PubMed ID: 31899799)
1. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
3. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
[TBL] [Abstract][Full Text] [Related]
4. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
5. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
6. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
7. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
8. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
9. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
Cho BS; Min GJ; Park SS; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Bone Marrow Transplant; 2021 Nov; 56(11):2682-2689. PubMed ID: 34183780
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
Sasaki K; Tsujimoto S; Miyake M; Uchiyama Y; Ikeda J; Yoshitomi M; Shimosato Y; Tokumasu M; Matsuo H; Yoshida K; Ohki K; Kaburagi T; Yamato G; Hara Y; Takeuchi M; Kinoshita A; Tomizawa D; Taga T; Adachi S; Tawa A; Horibe K; Hayashi Y; Matsumoto N; Ito S; Shiba N
Br J Haematol; 2021 Jul; 194(2):414-422. PubMed ID: 34120331
[TBL] [Abstract][Full Text] [Related]
12. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Duan W; Liu X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Zhao X; Qin Y; Shi H; Chang Y; Huang X; Jiang H
Br J Haematol; 2021 Jan; 192(2):265-271. PubMed ID: 32588434
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
14. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
[No Abstract] [Full Text] [Related]
16. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].
Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890
[No Abstract] [Full Text] [Related]
17. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
18. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
Duan W; Yang S; Zhao T; Hu L; Qin Y; Jia J; Wang J; Lu S; Jiang H; Zhang X; Xu L; Wang Y; Lai Y; Shi H; Huang X; Jiang Q
Ann Hematol; 2023 Oct; 102(10):2695-2705. PubMed ID: 37572135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
